Crestor ANDAs May Seek Approval For Unpatented Uses, Appeals Court Rules
Executive Summary
The Federal Circuit ruled that AstraZeneca cannot claim infringement of unpatented uses of rosuvastatin; the court affirmed the validity of section viii labeling carve-outs.